Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14005520 | 0.88 | KDR (0.45) | XDHSLC22A12PDPK1KDRCDK1 | |
| SCHEMBL14005508 | 0.85 | PLG (0.42) | XDHSLC22A12BRAFKDRFLT1 | |
| SCHEMBL14005511 | 0.84 | IKBKB (0.49) | XDHSLC22A12PDPK1IKBKBKDR | |
| SCHEMBL14068604 | 0.80 | PDPK1 (0.42) | XDHSLC22A12PDPK1BRAFNAMPT | |
| SCHEMBL14005522 | 0.79 | XDH (0.42) | XDHSLC22A12BRAFKDRFLT1 | |
| SCHEMBL14005526 | 0.79 | SLC22A12 (0.45) | XDHSLC22A12BRAFTAS2R14 | |
| SCHEMBL14031002 | 0.78 | XDH (0.48) | XDHSLC22A12PDPK1TRPV1BRAF | |
| SCHEMBL14005485 | 0.77 | RAB9A (0.53) | XDHSLC22A12PDPK1 | |
| SCHEMBL14005533 | 0.77 | SIRT2 (0.49) | XDHSLC22A12EPHX2KDRNAMPT | |
| SCHEMBL22042452 | 0.76 | PDPK1 (0.47) | XDHSLC22A12PDPK1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | XDH 2390/4885SLC22A12 4846/4885PDPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.